Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Risk behaviour and patient preferences for an improved non-melanoma skin cancer prevention modality for organ-transplanted patients; a European, multi-country, online patient community study.

Basset Seguin N, Malvehy J, Nadal F, Creancier L, Rauly-Lestienne I, Beauchamp R, Hezareh M, Schmitt AM, Ulianov L.

Eur J Dermatol. 2019 Oct 23. doi: 10.1684/ejd.2019.3639. [Epub ahead of print]

PMID:
31647462
2.

Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.

Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.

Vaccine. 2018 Apr 19;36(17):2356-2363. doi: 10.1016/j.vaccine.2018.02.085. Epub 2018 Mar 22.

3.

Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.

Cutland CL, Nolan T, Halperin SA, Kurugol Z, Ahmed K, Perrett KP, Richmond P, Marshall HS, Ceyhan M, Kolhe D, Hezareh M, Van Der Wielen M.

Vaccine. 2018 Mar 27;36(14):1908-1916. doi: 10.1016/j.vaccine.2018.02.013. Epub 2018 Mar 2.

4.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.

Leung TF, Liu AP, Lim FS, Thollot F, Oh HML, Lee BW, Rombo L, Tan NC, Rouzier R, De Simoni S, Suryakiran P, Hezareh M, Thomas F, Folschweiller N, Struyf F.

Vaccine. 2018 Jan 2;36(1):98-106. doi: 10.1016/j.vaccine.2017.11.034. Epub 2017 Nov 23.

5.

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.

Huang LM, Puthanakit T, Cheng-Hsun C, Ren-Bin T, Schwarz T, Pellegrino A, Esposito S, Frenette L, McNeil S, Durando P, Rheault P, Giaquinto C, Horn M, Petry KU, Peters K, Azhar T, Hillemanns P, De Simoni S, Friel D, Pemmaraju S, Hezareh M, Thomas F, Descamps D, Folschweiller N, Struyf F.

J Infect Dis. 2017 Jun 1;215(11):1711-1719. doi: 10.1093/infdis/jix154.

6.

Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART.

Beliakova-Bethell N, Hezareh M, Wong JK, Strain MC, Lewinski MK, Richman DD, Spina CA.

Virology. 2017 Aug;508:127-133. doi: 10.1016/j.virol.2017.05.008.

7.

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.

Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.

Hum Vaccin Immunother. 2017 Jul 3;13(7):1505-1515. doi: 10.1080/21645515.2017.1294294. Epub 2017 Mar 24.

8.

Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.

Vesikari T, Forsten A, Seppä I, Kaijalainen T, Puumalainen T, Soininen A, Traskine M, Lommel P, Schoonbroodt S, Hezareh M, Moreira M, Borys D, Schuerman L.

J Pediatric Infect Dis Soc. 2016 Sep;5(3):237-248. doi: 10.1093/jpids/piw010. Epub 2016 Apr 28.

9.

Motivations for Intravaginal Product Use among a Cohort of Women in Los Angeles.

Brown JM, Poirot E, Hess KL, Brown S, Vertucci M, Hezareh M.

PLoS One. 2016 Mar 11;11(3):e0151378. doi: 10.1371/journal.pone.0151378. eCollection 2016.

10.

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.

Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, Frenette L, Giaquinto C, McNeil S, Rheault P, Durando P, Horn M, Klar M, Poncelet S, De Simoni S, Friel D, De Muynck B, Suryakiran PV, Hezareh M, Descamps D, Thomas F, Struyf F.

J Infect Dis. 2016 Aug 15;214(4):525-36. doi: 10.1093/infdis/jiw036. Epub 2016 Feb 3.

11.

Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.

Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, Roy-Ghanta S.

Vaccine. 2016 Mar 14;34(12):1436-43. doi: 10.1016/j.vaccine.2016.02.010. Epub 2016 Feb 9.

12.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.

Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, Rombo L, Tan NC, Rouzier R, Friel D, De Muynck B, De Simoni S, Suryakiran P, Hezareh M, Folschweiller N, Thomas F, Struyf F.

Hum Vaccin Immunother. 2015;11(7):1689-702. doi: 10.1080/21645515.2015.1050570.

13.
14.

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.

Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, Durand C, Hervé C, Descamps D.

Vaccine. 2013 Nov 19;31(48):5745-53. doi: 10.1016/j.vaccine.2013.09.032. Epub 2013 Oct 1.

15.

Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States.

Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezareh M.

Obstet Gynecol. 2013 Apr;121(4):773-80. doi: 10.1097/AOG.0b013e31828786f8.

PMID:
23635677
16.

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.

Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, Schuerman L, Kilpi TM.

Lancet. 2013 Jan 19;381(9862):214-22. doi: 10.1016/S0140-6736(12)61854-6. Epub 2012 Nov 16. Erratum in: Lancet. 2013 May 18;381(9879):1720. Erratum in: Lancet. 2015 May 30;385(9983):2152.

PMID:
23158882
17.

Prostratin as a new therapeutic agent targeting HIV viral reservoirs.

Hezareh M.

Drug News Perspect. 2005 Oct;18(8):496-500. Review.

PMID:
16391719
18.

Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms.

Hezareh M, Moukil MA, Szanto I, Pondarzewski M, Mouche S, Cherix N, Brown SJ, Carpentier JL, Foti M.

Antivir Chem Chemother. 2004 Jul;15(4):207-22.

PMID:
15457682
19.

Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes.

Rullas J, Bermejo M, García-Pérez J, Beltán M, González N, Hezareh M, Brown SJ, Alcamí J.

Antivir Ther. 2004 Aug;9(4):545-54.

PMID:
15456086
20.

Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry.

Witvrouw M, Pannecouque C, Fikkert V, Hantson A, Van Remoortel B, Hezareh M, De Clercq E, Brown SJ.

Antivir Chem Chemother. 2003 Nov;14(6):321-8.

PMID:
14968938
21.

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW.

J Virol. 2001 Dec;75(24):12161-8.

22.

Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

Günthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, Spina CA, Havlir DV, Hezareh M, Looney DJ, Richman DD, Wong JK.

J Virol. 1999 Nov;73(11):9404-12.

23.

Stimulation of Ca2+ influx in alpha T3-1 gonadotrophs via the cAMP/PKA signaling system.

Hezareh M, Schlegel W, Rawlings SR.

Am J Physiol. 1997 Nov;273(5):E850-8. doi: 10.1152/ajpendo.1997.273.5.E850.

PMID:
9374669
24.

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD.

Science. 1997 Nov 14;278(5341):1291-5.

25.

PACAP/VIP receptor subtypes, signal transducers, and effectors in pituitary cells.

Hezareh M, Journot L, Bépoldin L, Schlegel W, Rawlings SR.

Ann N Y Acad Sci. 1996 Dec 26;805:315-27; discussion 327-8. Review.

PMID:
8993413
27.

Supplemental Content

Loading ...
Support Center